Kindler takes lumps after investor call

Poor Jeff Kindler (photo). The Pfizer CEO has finally done what analysts have wanted him to do for months and months: He made a big bold move, agreeing to buy Wyeth for more than $60 billion. But investors and pharma-watchers are still carping.

After a conference call earlier this week, commentators at Seeking Alpha allowed that Pfizer is a strong company whose stock looks "dirt cheap" at $14 per share, and that Pfizer seems likely to outperform the broader market. But, they said, "[W]e were not very impressed by CEO Jeff Kndler and CFO Frank D'Amelio's performance on the...call." Kindler and Co. were spouting business-school-speak, and their comments were too vague for comfort. "Nothing the executives said convinced us that the Wyeth deal with grow per-share shareholder value," they said.

Still, some interesting nuggets in that investor call, reported by The Day: Kindler said the Wyeth deal "changes the mix so we're not as dependent on a blockbuster-focused model." Strangely, Kindler followed that up by saying that the company had been too reliant "on research relative to its ability to deliver." What might this mean for Pfizer R&D? The only specifics came in the form of a promise that Wyeth's research staff will be melded with Pfizer's faster than with previous acquisitions. He's aiming to prevent the R&D snafus of the two other megamergers this decade, which dragged on research for years. We'll see how he fares.

- read the Seeking Alpha column
- see the story in The Day

ALSO: Pfizer stopped a late-stage study of the cancer drug Sutent to treat a form of advanced breast cancer but will continue examining the kidney-and-gastrointestinal cancer treatment in several other mid- and late-stage trials for breast disease. Report

ALSO: A lawyer representing Nigeria in multibillion dollar lawsuits against Pfizer said his clients would seriously consider a $75 million settlement, but that no official offer had yet been made by the company. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.